Michael Lübbert
A5047951694- Acute Myeloid Leukemia Research
- Epigenetics and DNA Methylation
- Histone Deacetylase Inhibitors Research
- Acute Lymphoblastic Leukemia research
- Protein Degradation and Inhibitors
- Chronic Myeloid Leukemia Treatments
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Retinoids in leukemia and cellular processes
- Hematopoietic Stem Cell Transplantation
- Chronic Lymphocytic Leukemia Research
- Multiple Myeloma Research and Treatments
- Cancer Genomics and Diagnostics
- Lymphoma Diagnosis and Treatment
- Cancer-related gene regulation
- Hemoglobinopathies and Related Disorders
- Hematological disorders and diagnostics
- RNA modifications and cancer
- RNA Interference and Gene Delivery
- Genomics and Chromatin Dynamics
- Pneumocystis jirovecii pneumonia detection and treatment
- Cancer-related Molecular Pathways
- Blood disorders and treatments
- HIV/AIDS drug development and treatment
- Sarcoma Diagnosis and Treatment
- Immune Cell Function and Interaction
University Medical Center Freiburg
2016-2025
University of Freiburg
2016-2025
Deutsche Gesellschaft für Hämatologie und Medizinische Onkologie
2025
German Cancer Research Center
2015-2024
Deutschen Konsortium für Translationale Krebsforschung
2016-2024
Heidelberg University
2015-2023
EFD Induction (Germany)
2023
German Marine Research Consortium
2021
Bernstein Center for Computational Neuroscience Freiburg
2019
University Medical Center Hamburg-Eppendorf
2011-2016
All-trans retinoic acid (ATRA) with chemotherapy is the standard of care for acute promyelocytic leukemia (APL), resulting in cure rates exceeding 80%. Pilot studies treatment arsenic trioxide or without ATRA have shown high efficacy and reduced hematologic toxicity.We conducted a phase 3, multicenter trial comparing plus patients APL classified as low-to-intermediate risk (white-cell count, ≤10×10(9) per liter). Patients were randomly assigned to receive either induction consolidation...
Purpose The karyotype is a strong independent prognostic factor in myelodysplastic syndromes (MDS). Since the implementation of International Prognostic Scoring System (IPSS) 1997, knowledge concerning impact abnormalities has increased substantially. present study proposes new and comprehensive cytogenetic scoring system based on an international data collection 2,902 patients. Patients Methods were included from German-Austrian MDS Study Group (n = 1,193), Risk Analysis Workshop 816),...
PURPOSE: 5-Aza-2′-deoxycytidine (decitabine; DAC) is a DNA hypomethylating agent that has shown 50% response rate in small phase II study elderly patients with high-risk myelodysplastic syndrome. We performed second, multicenter larger group of to confirm our findings and the toxicity DAC. PATIENTS AND METHODS: Between June 1996 September 1997, 66 (median age, 68 years) from seven centers received DAC 45 mg/m 2 /d for 3 days every 6 weeks. For whom complete (CR) was reached after two...
To compare low-dose decitabine to best supportive care (BSC) in higher-risk patients with myelodysplastic syndrome (MDS) age 60 years or older and ineligible for intensive chemotherapy.Two-hundred thirty-three (median age, 70 years; range, 90 years) were enrolled; 53% had poor-risk cytogenetics, the median MDS duration at random assignment was 3 months. Primary end point overall survival (OS). Decitabine (15 mg/m(2)) given intravenously over 4 hours three times a day days 6-week cycles.OS...
To evaluate the prognostic value of minimal residual disease (MRD) in patients with acute myeloid leukemia (AML) NPM1 mutation (NPM1(mut)).RNA-based real-time quantitative polymerase chain reaction (RQ-PCR) specific for detection six different NPM1(mut) types was applied to 1,682 samples (bone marrow, n = 1,272; blood, 410) serially obtained from 245 intensively treated younger adult who were 16 60 years old.NPM1(mut) transcript levels as a continuous variable significantly associated...
To study the incidence and prognostic impact of mutations in DNA methyltransferase 3A (DNMT3A) patients with acute myeloid leukemia.A total 489 AML were examined for DNMT3A by direct sequencing. The was evaluated context other clinical markers genetic risk factors (cytogenetic group; NPM1, FLT3, CEBPA, IDH1, IDH2, MLL1, NRAS, WT1, WT1 SNPrs16754; expression levels BAALC, ERG, EVI1, MLL5, MN1, WT1).DNMT3A found 87 (17.8%) who younger than 60 years age. Patients older, had higher WBC platelet...
Purpose The initial results of the APL0406 trial showed that combination all- trans-retinoic acid (ATRA) and arsenic trioxide (ATO) is at least not inferior to standard ATRA chemotherapy (CHT) in first-line therapy low- or intermediate-risk acute promyelocytic leukemia (APL). We herein report final analysis on complete series patients enrolled onto this trial. Patients Methods study was a prospective, randomized, multicenter, open-label, phase III noninferiority Eligible were adults between...
Research Article14 April 2015Open Access Source Data ZEB1-associated drug resistance in cancer cells is reversed by the class I HDAC inhibitor mocetinostat Simone Meidhof Department of General and Visceral Surgery, University Freiburg Medical Center, Freiburg, Germany Spemann Graduate School Biology Medicine (SGBM), Albert Ludwigs Faculty Biology, Search for more papers this author Brabletz Experimental I, Nikolaus-Fiebiger-Center Molecular Medicine, FAU Erlangen-Nürnberg, Erlangen, Waltraut...
// Peter Valent 1,2 , Attilio Orazi 3 David P. Steensma 4 Benjamin L. Ebert 5 Detlef Haase 6 Luca Malcovati 7 Arjan A. van de Loosdrecht 8 Torsten Haferlach 9 Theresia M. Westers Denise Wells 10 Aristoteles Giagounidis 11 Michael Loken Alberto Orfao 12 Lübbert 13 Arnold Ganser 14 Wolf-Karsten Hofmann 15 Kiyoyuki Ogata 16 Julie Schanz Marie C. Béné 17 Gregor Hoermann 18 Wolfgang R. Sperr Karl Sotlar 19 Bettelheim 20 Reinhard Stauder 21 Pfeilstöcker 22 Hans-Peter Horny...